Rybelsus® Lawsuit

The weight loss drug Rybelsus® may cause serious health complications like vision loss from non-arteritic anterior ischemic optic neuropathy (NAION) or stomach paralysis. Filing a Rybelsus lawsuit may allow you to seek compensation for the side effects you suffered.

At Sokolove Law, we’ve recovered over $10.5 Billion total for injured clients nationwide. Call (800) 995-1212 now for a free case review to see if we may be able to help with your Rybelsus lawsuit.

Get a Free Rybelsus Case Review

About the Semaglutide & Rybelsus Lawsuits

Manufactured by Danish company Novo Nordisk, Rybelsus is a semaglutide tablet used to help patients curb food cravings and lose weight.

Popular weight loss drugs like Rybelsus work by slowing digestion and making users feel full for longer periods. However, some users have developed serious side effects, leading them to take legal action against the drug’s manufacturer.

Find out more about semaglutide and Rybelsus lawsuits: 

  • Rybelsus lawsuits allege that Novo Nordisk failed to adequately warn patients about serious side effects, including vision loss from NAION and gastrointestinal injuries.
  • Rybelsus NAION lawsuits have been consolidated into a multidistrict litigation (MDL No. 3163) in the Eastern District of Pennsylvania.
  • At least 146 GLP-1 NAION lawsuits are currently pending in the MDL.
  • Victims may be able to seek compensation for their medical bills, pain and suffering, and more.

For over 45 years, Sokolove Law has helped families affected by dangerous pharmaceuticals or defective medical devices get justice, securing more than $1.6 Billion nationwide. See if you may be able to file a Rybelsus NAION lawsuit.

Get the Help You Deserve

If you or a loved one developed NAION after using Rybelsus, we may be able to help you pursue compensation for your injuries.

Contact Us Now

NAION & Rybelsus

Recent studies have raised concerns about a potential link between semaglutide medications like Rybelsus and NAION, a serious eye condition that can lead to vision loss and blindness.

After over 16,800 patients at Massachusetts Eye and Ear were evaluated by neuro-ophthalmologists, researchers compared the rate of NAION in patients prescribed semaglutide with those taking other medications and found a striking difference.

Find out more about the increased risk of NAION from Rybelsus: 

  • Diabetes: Patients with type 2 diabetes prescribed semaglutide were over 4 times more likely to develop NAION than those on other diabetes medications.
  • Obesity: Patients who were overweight or obese and prescribed semaglutide were over 7 times more likely to develop NAION than those on other weight-loss medications.

Despite growing evidence linking semaglutide to NAION, the Rybelsus warning label doesn’t currently list NAION as a known side effect.

Symptoms of NAION from Rybelsus

Because Rybelsus is taken daily, patients may not immediately connect changes in their vision to the medication.

However, NAION can develop in anyone taking a semaglutide medication, so it’s important for users to be aware of the warning signs of this condition.

Symptoms of NAION from Rybelsus may include: 

  • A dark, shadowy, or blank spot in part of your visual field
  • Dimming of vision or loss of contrast and color clarity
  • Sudden vision loss or blurriness in one eye, often noticed upon waking
  • Swelling of the optic nerve, which may be detected during an eye exam

If you are taking Rybelsus and experience any sudden changes in your vision, seek immediate medical attention. NAION can progress rapidly, and vision loss from this condition is often permanent and irreversible.

Who Can File a Rybelsus Lawsuit?

Rybelsus lawsuit eligibility generally depends on whether you were prescribed a semaglutide medication and if you were later diagnosed with NAION or another serious side effect.

You may be able to file a Rybelsus lawsuit if you or a loved one:

  • Used Rybelsus or another GLP-1 like Ozempic, Mounjaro, Saxenda, Trulicity, Wegovy, or Zepbound
  • Suffered serious health issues like vision loss linked to non-arteritic anterior ischemic optic neuropathy (NAION)

However, you only have a limited amount of time to file a Rybelsus NAION lawsuit due to state deadlines known as the statute of limitations.

Call (800) 995-1212 as soon as possible for free help determining your Rybelsus lawsuit eligibility before the deadline passes.

Filing a Rybelsus NAION Lawsuit: 4 Quick Steps

At Sokolove Law, our Rybelsus attorneys have the experience, resources, and skills needed to level the playing field between victims and the drug manufacturers responsible for their injuries.

To make everything as stress-free as possible, we’ll handle every step of the legal process on your behalf. This way, you can focus on what matters most: your health and well-being.

Filing a Rybelsus NAION lawsuit generally involves these four steps:

  1. Contact Rybelsus Lawyers: Sokolove Law provides all clients with free legal case reviews to determine their eligibility to take legal action.
  2. Building the Case: Our Rybelsus lawyers will gather evidence to build a strong case on your behalf, including medical records, testimony, and more.
  3. Filing Your Rybelsus Claim: Your attorneys can make sure all paperwork is completed and your lawsuit is filed before any legal deadlines in your state.
  4. Securing Compensation: We’ll work to secure a Rybelsus settlement out of court if possible, though we’ll be prepared to present your case in a court trial if needed.

Let us get you the money you deserve. Call (800) 995-1212 now to get started for free.

Let Our Rybelsus Lawsuit Lawyers Fight for You

As a national dangerous drug law firm, Sokolove Law is prepared to help families affected by dangerous semaglutide weight loss drugs like Ozempic, Wegovy, and Rybelsus get justice and compensation for their side effects.

Why choose Rybelsus lawyers with Sokolove Law?

  • Over 45 Years of Experience: Since 1979, Sokolove Law has helped thousands of clients injured through no fault of their own.
  • Billions of Dollars in Results: We’ve secured more than $10.5 Billion total — including over $1.6 Billion from prescription drug and medical device cases.
  • Legal Help in All 50 States: Wherever you may be in the U.S., our Rybelsus attorneys are here to help since we can file claims nationwide.
  • No Hourly Fees or Upfront Costs: Our team only gets paid if we’re able to successfully secure compensation for you. There aren’t any out-of-pocket expenses.

Let our Rybelsus attorneys fight for your family. Call (800) 995-1212 now or fill out our contact form for a free, no-obligation case review.

Note: Do not change medications without first consulting your doctor. All brands are trademarks of their respective companies.

NAION Rybelsus Lawsuit FAQs

What is the Rybelsus controversy?

Rybelsus users across the country have reported suffering gastroparesis, vision loss from non-arteritic anterior ischemic optic neuropathy (NAION), and other side effects from using semaglutide weight loss drugs.

To date, at least 146 NAION lawsuits have been filed by patients who feel as though they weren’t properly warned about the risk of vision loss.

Contact Sokolove Law now to see if you may be eligible for compensation from a Rybelsus lawsuit.

Can Rybelsus cause eye problems?

Yes. The use of Rybelsus has been linked to non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye problem that can cause vision loss and blindness.

Patients taking semaglutide, the active ingredient in Rybelsus, are more likely to be diagnosed with NAION compared to patients taking other medications for diabetes or obesity, according to a study published in JAMA Ophthalmology.

Who is eligible to join the Rybelsus lawsuit?

Rybelsus lawsuit eligibility revolves around whether you or a loved one:

  • Used a GLP-1 like Rybelsus, Mounjaro, Ozempic, Saxenda, Trulicity, Wegovy, or Zepbound
  • Suffered semaglutide side effects like vision loss from non-arteritic anterior ischemic optic neuropathy (NAION)
  • File your claim before the statute of limitations or legal deadline passes in your case

Don’t miss your chance to seek justice and compensation from the company responsible for your injuries.

Get free help determining your eligibility to file a Rybelsus lawsuit now.

Is there a Rybelsus class action lawsuit?

Multiple Rybelsus lawsuits have been filed across the country and consolidated into multidistrict litigation (MDL) proceedings in the U.S. District Court for the Eastern District of Pennsylvania.

At least 146 GLP-1 NAION lawsuits for vision loss are currently pending in MDL No. 3163, including claims involving Rybelsus. Approximately 3,848 lawsuits for gastrointestinal issues from Rybelsus and other GLP-1s are pending in MDL No. 3094

Call (800) 995-1212 now to learn more about your legal options during a free case review.

What is the lawsuit against semaglutide weight loss drugs?

Lawsuits against semaglutide weight loss drugs like Rybelsus claim manufacturers failed to notify patients about serious side effects that may occur when taking these medications, like vision loss or blindness from non-arteritic anterior ischemic optic neuropathy (NAION).

There are currently 146 NAION claims pending in a multidistrict litigation (MDL) against the manufacturers of tirzepatide and semaglutide medications, including Rybelsus.

What are common Rybelsus side effects?

Patients taking Rybelsus may experience several serious side effects, such as blindness and digestive issues.

Side effects of Rybelsus can include:

  • Vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)
  • Stomach paralysis (gastroparesis)
  • Bowel or intestinal obstructions
  • Chronic vomiting
  • Deep vein thrombosis (DVT)
  • Esophageal injury
  • Ileus (intestinal inability to contract and pass waste)
  • Intraoperative pulmonary aspiration
  • Malnutrition-related disorders
  • Pancreatic cancer

If you experienced any serious side effects from Rybelsus, contact Sokolove Law now to learn more about your potential legal options.

How does Rybelsus work?

Rybelsus mimics the effects of GLP-1, a hormone that helps regulate blood sugar levels. This weight loss drug slows digestion and boosts insulin production, which may allow patients to feel full for longer.

However, because Rybelsus affects blood vessel function and circulation throughout the body, some researchers believe it may reduce blood flow to the optic nerve and contribute to the development of NAION and sudden vision loss.

Additionally, its effect on slowing digestion has been linked to serious gastrointestinal complications in some users, including stomach paralysis.

Does Rybelsus cause gastroparesis?

Potentially, yes. Recent studies have shown that semaglutide medications like Rybelsus can increase the risk of gastroparesis, bowel obstructions, vision loss, and other serious health issues.

  1. American Academy of Ophthalmology. "American Academy of Ophthalmology and North American Neuro-Ophthalmology Society Issue Advice on Weight Loss Drug and Eye Health." Retrieved from: https://www.aao.org/newsroom/news-releases/detail/weight-loss-drug-and-eye-health
  2. Clinical Practice and Surgical Cases. ”Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication.”  Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12372079/.
  3. JAMA Network. “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.” Retrieved from: https://jamanetwork.com/journals/jama/fullarticle/2810542.
  4. JAMA Ophthalmology. “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.” Retrieved from: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255.
  5. PHILADELPHIA COUNTY COURT OF COMMON PLEAS. “Kelly Miller vs. Novo Nordisk.” Retrieved from: https://fjdefile.phila.gov/efsfjd/zk_fjd_public_qry_00.zp_add_to_cart?uid=MhjHIrvGAIolqsSYDxam&o=VmpS_1o9WxozKg8&c=230901944&d=3&b=1&tfn=lZ8!PbJ6K.pdf.
  6. U.S. Food and Drug Administration. “HIGHLIGHTS OF PRESCRIBING INFORMATION.” Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s005lbl.pdf.
  7. U.S. Food and Drug Administration. “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.” Retrieved from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss.